Breast cancer still remains a challenge worldwide, as many breast cancer patients are
developing resistance to conventional therapies. Nanomedicine is among one of the
important approaches, which increases the therapeutic potential of the existing drugs by
delivering anticancer drugs at their target sites. These nanomedicines of anticancer drugs
need to be evaluated in a relevant preclinical animal model before being tested in human
being for assessing their pharmacokinetic and pharmacodynamic (PK-PD) behaviors …